Antibe Therapeutics (TSX:ATE) Price-to-Tangible-Book : (As of May. 24, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Price-to-Tangible-Book?

As of today (2024-05-24), Antibe Therapeutics's share price is C$0.295. Antibe Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was C$-0.01. Hence, Antibe Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Antibe Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 12 years, Antibe Therapeutics's highest Price to Tangible Book Ratio was 89.71. The lowest was 0.98. And the median was 9.33.

TSX:ATE's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.78
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Antibe Therapeutics's share price is C$0.295. Antibe Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was C$0.49. Hence, Antibe Therapeutics's P/B Ratio of today is 0.60.

Antibe Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Antibe Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Price-to-Tangible-Book Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Price-to-Tangible-Book

Get a 7-Day Free Trial

18.63

89.71

4.71

1.35

2.28

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															1.46	2.28	2.88	7.66	-

Competitive Comparison of Antibe Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Antibe Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Price-to-Tangible-Book falls into.

Antibe Therapeutics Price-to-Tangible-Book Calculation

Antibe Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.295	/	-0.008
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Antibe Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines